[144] Metallus Inc. SEC Filing

Rhea-AI Filing Summary

On 30 June 2025, SANUWAVE Health, Inc. (ticker: SNWV) granted Director Jeffrey Blizard a fully-vested stock option covering 1,574 shares of common stock, as disclosed in a Form 4 filed on 2 July 2025. The option carries an exercise price of $32.86 and an expiration date of 30 June 2030. The transaction was coded “A,” indicating an issuer-awarded grant rather than an open-market purchase. No non-derivative transactions or additional derivative movements were reported.

Following this grant, Mr. Blizard directly owns 1,574 derivative securities and reported no other holdings in SNWV common stock. Because the options were already fully vested at issuance, they are immediately exercisable, potentially aligning the director’s incentives with shareholder value creation. However, the filing does not specify any accompanying cash outlay or further equity activity.

Positive

• Director-shareholder alignment: Option grant provides equity-based incentive that can align the director’s interests with long-term shareholder value.

Negative

• Potential dilution: Issuance of new options adds 1,574 shares of potential dilution, though the amount appears immaterial.

Insights

Corporate Governance Analyst

TL;DR – Routine director option grant; negligible immediate impact on valuation.

The Form 4 shows a standard equity incentive: 1,574 fully-vested options to Director Jeffrey Blizard at a $32.86 strike, expiring in 2030. No common-stock sales or purchases occurred. The modest size suggests minimal dilution and limited near-term financial effect. While the grant marginally strengthens pay-for-performance alignment, it is too small to materially move SNWV’s capital structure or governance profile. Overall impact on investors is neutral.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	MERRILL LYNCH 3455 PEACHTREE RD NE SUITE 1000 ATLANTA GA 30326	4000	64000.00	42023268	07/02/2025	NEW YORK

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	02/06/2024	PERFORMANCE STOCK UNIT VEST	METALLUS INC			4000	02/06/2024	COMPENSATORY PAYMENT

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What transaction did Director Jeffrey Blizard report for SNWV?

A fully-vested option grant covering 1,574 shares of SNWV common stock.

How many stock options were granted to Jeffrey Blizard?

The Form 4 reports 1,574 stock options.

What is the exercise price and expiration date of the options?

The options have a $32.86 exercise price and expire on 30 June 2030.

Were the options immediately vested?

Yes. The filing states the options were fully vested on the grant date.

How many derivative securities does Mr. Blizard own after the transaction?

He beneficially owns 1,574 derivative securities following the reported grant.

When was the Form 4 filed?

The Form 4 was filed on 2 July 2025.